Most brain arteriovenous malformations (AVMs) are diagnosed through a combination of imaging scans, starting with CT or MRI and confirmed with a specialized procedure called cerebral angiography. Around 40 to 65% of AVMs are discovered after a hemorrhage, while roughly 15% are found incidentally during brain imaging done for an unrelated reason, like a headache workup or head injury.
How AVMs Are First Detected
AVMs rarely announce themselves before something goes wrong. When they do cause symptoms, the signs can include seizures, persistent headaches, weakness or numbness on one side of the body, vision changes, or difficulty speaking. These symptoms overlap with many other conditions, so imaging is essential to pin down the cause. In some cases, a doctor can hear a whooshing sound (called a bruit) when listening to the skull with a stethoscope, which signals abnormal blood flow and prompts further testing.
For the 15% of people whose AVMs are found by accident, the discovery typically happens during a CT or MRI ordered for something else entirely. This can be unsettling, but it also means the AVM is caught before it causes damage.
CT Scans and MRI: The First Imaging Step
When a doctor suspects something abnormal in the brain, a CT scan or MRI is usually the first test ordered. Both are noninvasive, widely available, and effective at spotting AVMs. In a study of 125 patients, CT angiography (a CT scan enhanced with contrast dye) detected AVMs with 90% sensitivity, while standard MRI detected them at 89%. For AVMs larger than 3 centimeters, both methods caught 100% of cases.
These numbers drop slightly when an AVM has already ruptured, because bleeding can obscure the malformation on imaging. In ruptured cases, CT angiography sensitivity fell to 87% and MRI to 83%. Magnetic resonance angiography (MRA), a version of MRI focused specifically on blood vessels, performed lower across the board at around 74% overall.
A CT angiography involves placing an IV, injecting a contrast dye into a vein, and lying still while the scanner captures images. Most people feel a brief warming sensation as the dye enters the bloodstream, which fades quickly. If you have a known allergy to contrast dye, your doctor may ask you to take medication for 24 hours beforehand to reduce the risk of a reaction.
Cerebral Angiography: The Gold Standard
While CT and MRI can detect an AVM, they can’t provide the level of detail needed for treatment planning. Cerebral angiography, specifically digital subtraction angiography (DSA), remains the gold standard. This procedure maps the AVM’s complete architecture: which arteries feed into it, where the tangled core (called the nidus) sits, how blood drains out through the veins, and whether there are any associated aneurysms or narrowed vessels nearby. All of this information is critical for deciding whether and how to treat the AVM.
Unlike a CT angiogram, which injects dye into a vein, a cerebral angiogram threads a thin catheter into an artery, typically through the groin or wrist, and guides it up to the blood vessels in the brain. Contrast dye is then injected directly, and rapid X-ray images capture the flow of blood through the AVM in real time. This gives doctors a dynamic view that no other test can match, showing not just the structure but also how fast blood moves through the malformation.
The procedure carries small but real risks, including a 0.3% to 2.6% chance of neurologic complications. Because of this, it’s generally performed after a CT or MRI has already raised suspicion of an AVM, not as a first-line screening tool.
Newer Imaging With 4D MRA
A technique called 4D contrast-enhanced MRA aims to bridge the gap between standard MRI and catheter-based angiography. It produces dynamic, “DSA-like” images that show arterial feeders, the nidus, and draining veins in a single exam, all without threading a catheter into an artery or exposing the patient to radiation.
The tradeoff is accuracy. In studies comparing 4D MRA to traditional angiography for treated AVMs, 4D MRA reached a sensitivity of about 74%, meaning it missed roughly one in four residual AVMs. Its specificity was 100%, so when it did identify an AVM, it was always correct. This makes 4D MRA a useful monitoring tool, particularly after radiosurgery, but it isn’t reliable enough on its own to confirm that an AVM is fully cured. Traditional angiography is still required for that determination.
How AVMs Are Graded After Diagnosis
Once an AVM is confirmed, doctors classify it using the Spetzler-Martin grading system, which scores the malformation on three factors: its size, whether it drains through deep or superficial veins, and whether it sits near areas of the brain that control essential functions like speech, movement, or vision. Each factor adds points, producing a grade from 1 to 5. Lower grades indicate AVMs that are smaller, in less critical locations, and generally safer to treat surgically. Higher grades suggest greater complexity and risk.
This grading doesn’t change the diagnosis itself, but it directly shapes the treatment conversation. A grade 1 AVM might be a strong candidate for surgery, while a grade 5 AVM might be better managed with observation or less invasive approaches.
Distinguishing AVMs From Similar Conditions
Not every tangle of abnormal blood vessels in the brain is an AVM. Cavernous malformations, for example, look different on imaging and behave differently. They are made up of slow-moving, low-pressure blood channels and are characteristically invisible on angiography because blood transits through them too slowly to show up. An AVM, by contrast, is a high-flow lesion that lights up clearly on angiography. The presence of a developmental venous anomaly alongside the lesion strongly supports a diagnosis of cavernous malformation rather than AVM. These distinctions matter because the conditions carry different risks and require different treatment strategies.
Screening for People With a Genetic Link
One group of people may undergo AVM screening even without symptoms: those with hereditary hemorrhagic telangiectasia (HHT), a genetic condition that significantly raises the risk of developing AVMs in the brain, lungs, and other organs. Current guidelines recommend a brain MRI with and without contrast for anyone diagnosed with HHT or at risk based on family history.
For children who have their first brain MRI early in life, a repeat scan is typically recommended by age 18 to 20, since AVMs can develop or change during the first two decades. Screening for lung AVMs uses a heart ultrasound with agitated saline contrast (a bubble study) rather than a CT scan, and this is generally repeated every five years if results are normal. For at-risk family members under 40 who haven’t been ruled out through genetic testing, the recommendation is to follow the same screening schedule as those with a confirmed HHT diagnosis.